Evidence map›Paper›PMID 35672339›Full record

ArticleScientific reports2022

Dynamic insights into the effects of nonsynonymous polymorphisms (nsSNPs) on loss of TREM2 function.

Raju Dash, Yeasmin Akter Munni, Sarmistha Mitra, Ho Jin Choi, Sultana Israt Jahan, Apusi Chowdhury, Tae Jung Jang, Il Soo Moon

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Cholecalciferol (vitamin D3) is an agonist of the Alzheimer's disease-associated immune receptor TREM2.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  3. Article
  4. Synergistic reduction in interfacial flexibility of TREM2Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  5. Article
  6. Dehydroervatamine as a promising novel TREM2 agonist, attenuates neuroinflammation.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Raju DashDepartment of Anatomy, Dongguk University College of Medicine, Gyeongju, 38066, Republic of Korea.
Yeasmin Akter MunniDepartment of Anatomy, Dongguk University College of Medicine, Gyeongju, 38066, Republic of Korea.
Sarmistha MitraDepartment of Anatomy, Dongguk University College of Medicine, Gyeongju, 38066, Republic of Korea.
Ho Jin ChoiDepartment of Anatomy, Dongguk University College of Medicine, Gyeongju, 38066, Republic of Korea.
Sultana Israt JahanDepartment of Biotechnology and Genetic Engineering, Noakhali Science and Technology University, Noakhali, 3814, Bangladesh.
Apusi ChowdhuryDepartment of Pharmaceutical Science, North-South University, Dhaka, 1229, Bangladesh.
Tae Jung JangDepartment of Pathology, Dongguk University College of Medicine, Gyeongju, 38066, Republic of Korea.
Il Soo MoonDepartment of Anatomy, Dongguk University College of Medicine, Gyeongju, 38066, Republic of Korea. moonis@dongguk.ac.kr.
Dongguk University · KRNoakhali Science and Technology University · BDNorth South University · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single nucleotide variations in Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) are associated with many neurodegenerative diseases, including Nasu-Hakola disease (NHD), frontotemporal dementia (FTD), and late-onset Alzheimer's disease because they disrupt ligand binding to the extracellular domain of TREM2. However, the effects of nonsynonymous single nucleotide polymorphisms (nsSNPs) in TREM2 on disease progression remain unknown. In this study, we identified several high-risk nsSNPs in the TREM2 gene using various deleterious SNP predicting algorithms and analyzed their destabilizing effects on the ligand recognizing region of the TREM2 immunoglobulin (Ig) domain by molecular dynamics (MD) simulation. Cumulative prediction by all tools employed suggested the three most deleterious nsSNPs involved in loss of TREM2 function are rs549402254 (W50S), rs749358844 (R52C), and rs1409131974 (D104G). MD simulation showed that these three variants cause substantial structural alterations and conformational remodeling of the apical loops of the TREM2 Ig domain, which is responsible for ligand recognition. Detailed analysis revealed that these variants substantially increased distances between apical loops and induced conformation remodeling by changing inter-loop nonbonded contacts. Moreover, all nsSNPs changed the electrostatic potentials near the putative ligand-interacting region (PLIR), which suggested they might reduce specificity or loss of binding affinity for TREM2 ligands. Overall, this study identifies three potential high-risk nsSNPs in the TREM2 gene. We propose further studies on the molecular mechanisms responsible for loss of TREM2 function and the associations between TREM2 nsSNPs and neurodegenerative diseases.

Indexed as

Frontotemporal DementiaNeurodegenerative DiseasesOsteochondrodysplasiasSubacute Sclerosing PanencephalitisHumansLigandsMembrane GlycoproteinsPolymorphism, Single NucleotideReceptors, ImmunologicLigandsMembrane GlycoproteinsReceptors, ImmunologicTREM2 protein, human

Identifiers

PMID35672339
PMCPMC9174165
OpenAlexW4282036169

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.